BioClinica Launches New IVR/IWR Platform, Trident IWR
BioClinica, Inc. announced the launch of its new IVR/IWR (interactive voice response/interactive web response) platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference (SCDM). Trident IWR’s interface provides clinical operations personnel with an intuitive and faster way to directly set up, monitor, and maintain randomization and supplies for their clinical trials.
“We believe that Trident will fundamentally change the IVR/IWR market. Trident gives customers the ability to build complex trials in a quicker and less costly manner than previous alternatives which require the development of custom programming for each new clinical trial,” said Mark Weinstein, CEO of BioClinica.
Designed from inception as a web-based system, Trident simultaneously delivers IVR phone support through the same simplified configuration process. It is fully synchronized with BioClinica Optimizer a clinical supply simulation and visualization package. Study designs simulated in Optimizer can configure Trident IWR to precisely match the optimal scenario identified using Optimizer. After deployment, Trident data can update Optimizer, and then Optimizer can re-simulate and reforecast. BioClinica will conduct educational Trident-related webinars beginning in November 2010. For more information about these sessions please visit: http://www.bioclinica.com/webinars/.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
